Analyst: New Genmab approval shows portfolio potential
The approval of the drug Tivdak, which is developed by Genmab and its partner Seagen, is in many ways a milestone achievement for the Danish biotech company, explains Senior Analyst at Sydbank Søren Løntoft Hansen.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
This isn't the first approval of a Genmab-developed drug, nor is it the first cancer drug that the Danish biotech company is behind. Nonetheless, the approval of tisotumab vedotin, under the commercial name Tivdak, by the US Food and Drug Administration (FDA) is an important stepping stone on the path forward, says Søren Løntoft Hansen, senior analyst at Sydbank.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
